Get the Stockscreener App
36.17
1.03%
0.37
After Hours:
35.97
-0.20
-0.55%
Septerna Inc stock is traded at $36.17, with a volume of 283.32K.
It is up +1.03% in the last 24 hours and up +37.53% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$35.80
Open:
$36.24
24h Volume:
283.32K
Relative Volume:
0.90
Market Cap:
$1.63B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-32.50
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
+6.29%
1M Performance:
+37.53%
6M Performance:
+31.34%
1Y Performance:
+244.80%
1-Day Range:
$34.51
$37.32
1-Week Range:
$33.85
$37.32
52-Week Range:
$9.96
$37.32
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
36.17 | 1.61B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Septerna Inc (SEPN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Septerna Inc (SEPN) Institutional Confidence - TradingKey
Septerna Inc (SEPN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Septerna Inc (SEPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Septerna Inc (SEPN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Septerna: A De-Risking GPCR Story With Near-Term Upside Catalysts - Seeking Alpha
Septerna’s chief people officer sells $219k in shares - Investing.com UK
Septerna (SEPN) Chief People Officer sells 6,250 shares after option exercise - Stock Titan
Septerna Inc. (SEPN) Edges Lower 1.22% as Stock Nears Support ThresholdAdaptive Moving Average - newsline.com
Septerna Inc (SEPN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Septerna Inc (SEPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Septerna Inc (SEPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Septerna Inc. (SEPN) Jumps 5.6% as Shares Test Key Resistance LevelVolatility Term Structure - newsline.com
SEPN Q1 2026 Earnings: Narrower Loss Beats Expectations, Shares RiseProfit Margin Analysis - newsline.com
SEPN: 8,428 shares proposed sale; Samira Shaikhly 10b5-1 sales listed - Stock Titan
Septerna (SEPN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Guggenheim Initiates Septerna at Buy With $52 Price Target - Moomoo
Septerna Inc stock reaches all-time high at 32.76 USD By Investing.com - Investing.com Nigeria
Septerna Inc stock reaches all-time high at 32.76 USD - Investing.com
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative? - simplywall.st
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting - Lelezard
Raymond James raises Septerna stock price target on pipeline potential - Investing.com UK
Experimental oral hypoparathyroidism drug SEP-479 gets ENDO 2026 stage - Stock Titan
Raymond James raises Septerna stock price target on pipeline potential By Investing.com - Investing.com Australia
Raymond James Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $53 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Septerna’s chief people officer sells $171,682 in stock By Investing.com - Investing.com Australia
Septerna’s chief people officer sells $171,682 in stock - Investing.com
Septerna (SEPN) CPO sells 5,935 shares under Rule 10b5-1 plan - Stock Titan
SEPN Q1 2026 Earnings: Smaller-Than-Expected Loss Reflects Operational DisciplineNegative Surprise Momentum - newsline.com
Septerna Inc. (SEPN) Slips 2.74% as Stock Tests Key Support LevelsContinuation Pattern Picks - The Legal Advocate
Septerna chief people officer Samira Shaikhly sells $354,656 common stock By Investing.com - Investing.com South Africa
Septerna Inc. (SEPN) Faces Pressure: Key Support Levels in Focus Amid 3.77% DeclineAndrews Pitchfork - The Legal Advocate
SEPN Q1 2026 Earnings: EPS Beat Drives Optimism Amid Pre-Revenue PhaseProfit Growth Outlook - newsline.com
Septerna (SEPN) Chief People Officer exercises options and sells 11,798 shares - Stock Titan
Septerna Inc. (SEPN) Surges 8% as Bullish Momentum BuildsSentiment Shift - The Legal Advocate
SEPN (NASDAQ: SEPN) option exercise sale of 11,798 shares on 05/26/2026 - Stock Titan
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026 - TipRanks
Septerna Inc. Q1 2026 Earnings: Narrower‑Than‑Expected Loss Boosts Investor SentimentGuidance Upgrade Report - The Legal Advocate
SEPN Q1 2026 Earnings: Smaller-Than-Expected Loss Amidst Pipeline ProgressEarnings Revision Downgrade - Newser
SEPN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineExpert Momentum Signals - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseCommunity Pattern Alerts - Newser
Septerna Inc. (SEPN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineROA Comparison - Newser
New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN) - Sahm
Septerna, Inc. (SEPN) Competitors - Meyka
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):